Accelerated Approvals Perked Up While US FDA Excelled At Being Average In 2025

 
• By Bridget Silverman
  
While most US FDA performance metrics for novel agents matched the 10-year average, accelerated approvals increased in 2025. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pink Sheet Perspectives

More from Pink Sheet